Last reviewed · How we verify
preservative-free 0.9% saline.
Preservative-free 0.9% saline is an isotonic solution that helps maintain fluid balance and electrolyte levels in the body.
Preservative-free 0.9% saline is an isotonic solution that helps maintain fluid balance and electrolyte levels in the body. Used for Treatment of dehydration due to various causes, including gastrointestinal fluid loss, excessive sweating, and burns.
At a glance
| Generic name | preservative-free 0.9% saline. |
|---|---|
| Sponsor | Al-Azhar University |
| Drug class | Crystalloid solution |
| Modality | Small molecule |
| Therapeutic area | Fluid and electrolyte management |
| Phase | Phase 3 |
Mechanism of action
It works by providing a balanced mixture of sodium chloride and water that closely matches the body's natural fluids, allowing for the replenishment of lost fluids and electrolytes without causing an imbalance. This can be particularly useful in medical settings where patients may be at risk of dehydration or electrolyte disturbances.
Approved indications
- Treatment of dehydration due to various causes, including gastrointestinal fluid loss, excessive sweating, and burns
Common side effects
- Hypersensitivity reactions
Key clinical trials
- Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer (PHASE2)
- A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03. (PHASE2)
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- OnabotulinumtoxinA for Trigeminal Neuralgia (PHASE4)
- Efficacy and Safety of Intrathecal Morphine for Postoperative Pain Management Following Planned Caesarean Section (PHASE4)
- A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses (PHASE1, PHASE2)
- COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (PHASE2)
- A Study of DCR-STAT3 in Adults With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- preservative-free 0.9% saline. CI brief — competitive landscape report
- preservative-free 0.9% saline. updates RSS · CI watch RSS
- Al-Azhar University portfolio CI